Scientists at the Salk Institute say they have found that an experimental drug candidate aimed at combating Alzheimer's disease has a host of unexpected anti-aging effects in animals.
The Salk team expanded upon their previous development of a drug candidate, called J147, which takes a different tack by targeting Alzheimer's major risk factor: old age. In the new work, the team showed that J147 worked well in a mouse model of aging not typically used in Alzheimer's research. When these mice were treated with J147, they had better memory and cognition, healthier blood vessels in the brain and other improved physiological features.
The team’s study (“A comprehensive multiomics approach toward understanding the relationship between aging and dementia”) is published in Aging.
“Initially, the impetus was to test this drug in a novel animal model that was more similar to 99 percent of Alzheimer's cases,” says Antonio Currais, Ph.D., the lead author and a member of the Schubert Cellular Neurobiology Laboratory at Salk. “We did not predict we'd see this sort of anti-aging effect, but J147 made old mice look like they were young, based upon a number of physiological parameters.”
“While most drugs developed in the past 20 years target the amyloid plaque deposits in the brain (which are a hallmark of the disease), none have proven effective in the clinic,” says David Schubert, Ph.D., senior author of the study.
Several years ago, Dr. Schubert and his colleagues began to approach the treatment of the disease from a new angle. Rather than target amyloid, the lab decided to zero in old age. Using cell-based screens against old age-associated brain toxicities, they synthesized J147.
Previously, the team found that J147 could prevent and even reverse memory loss and Alzheimer's pathology in mice that have a version of the inherited form of Alzheimer's, the most commonly used mouse model. However, this form of the disease comprises only about 1% of Alzheimer's cases. For everyone else, old age is the primary risk factor, according to Dr. Schubert. The team wanted to explore the effects of the drug candidate on a breed of mice that age rapidly and experience a version of dementia that more closely resembles the age-related human disorder.
In this latest work, the researchers used a comprehensive set of assays to measure the expression of all genes in the brain, as well as over 500 small molecules involved with metabolism in the brains and blood of three groups of the rapidly aging mice. The three groups of rapidly aging mice included one set that was young, one set that was old, and one set that was old but fed J147 as they aged.
The old mice that received J147 performed better on memory and other tests for cognition and also displayed more robust motor movements. The mice treated with J147 also had fewer pathological signs of Alzheimer's in their brains. Importantly, because of the large amount of data collected on the three groups of mice, it was possible to demonstrate that many aspects of gene expression and metabolism in the old mice fed J147 were very similar to those of the young animals. These included markers for increased energy metabolism, reduced brain inflammation and reduced levels of oxidized fatty acids in the brain.
Another notable effect was that J147 prevented the leakage of blood from the microvessels in the brains of old mice. “Damaged blood vessels are a common feature of aging in general, and in Alzheimer's, it is frequently much worse,” points out Dr. Currais.
While these studies represent a new and exciting approach to Alzheimer's drug discovery and animal testing in the context of aging, the only way to demonstrate the clinical relevance of the work is to move J147 into clinical trials for Alzheimer's disease, note the researchers.
“If proven safe and effective for Alzheimer's, the apparent anti-aging effect of J147 would be a welcome benefit,” adds Dr. Schubert. The team aims to begin human trials next year.